NCT00001123CompletedNot Applicable
A Collaborative Double-Blind Placebo-Controlled Trial of Intravenous Ribavirin As a Treatment for Presumed Hantavirus Pulmonary Syndrome
National Institute of Allergy and Infectious Diseases (NIAID)2 sites in 1 country130 target enrollmentStarted: August 31, 2001Last updated:
Conditions
Drugs
Trial Snapshot
- Phase
- Not Applicable
- Status
- Completed
- Enrollment
- 130
- Locations
- 2
Study Overview
Brief Summary
The purpose is to test the safety and effectiveness of intravenous ribavirin therapy in persons with suspected and subsequently proven hantavirus infection. The hantavirus is spread through the air into the lungs when dry rodent feces are moved or disturbed. It is characterized by fever and bleeding.
Detailed Description
Patients are randomized to receive either ribavirin or a placebo for 7 days. At the completion of therapy, patients will be seen on follow-up visits on days 14, 28, and 84.
Study Design
- Study Type
- Interventional
- Primary Purpose
- Treatment
- Masking
- Double
Eligibility Criteria
- Ages
- 12 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •You may be eligible for this study if you:
- •Are 12 years of age or older.
- •Are not pregnant.
- •Agree to practice sexual abstinence or use accepted barrier methods of birth control/contraception.
- •Are not breast-feeding.
- •Have a positive blood test for hantavirus.
- •Have symptoms suggestive of hantavirus illness.
Exclusion Criteria
- •You will not be eligible for this study if you:
- •Have severe low blood count (anemia).
- •Have a diagnosis of other respiratory viruses (influenza, RSV, etc.).
- •Have group A Streptococcus with symptoms of streptococcal pharyngitis, a positive culture from a normally sterile site, or symptoms of bacterial pneumonia.
- •Are HIV positive.
- •Have cancer.
- •Have had any period of irregular heartbeat.
- •Have had chemotherapy or other drugs that suppress the immune system within 30 days.
- •Have taken by mouth or injection any antiviral drug (other than acyclovir, famciclovir, amantadine or rimantadine.)
- •Have taken by mouth or injection corticosteroids equivalent to approximately 0.5 mg/kg prednisone.
- •Have taken any experimental drug within 30 days prior to enrollment.
Investigators
Study Sites (2)
Loading locations...
Similar Trials
Completed
Phase 3
Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment NaiveChronic Hepatitis CNCT00093093Bausch Health Americas, Inc.900
Completed
Phase 3
Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment-NaiveChronic Hepatitis CNCT00230958Bausch Health Americas, Inc.900
Unknown
Not Applicable
A Multi-centre, Double-blinded, Randomized, Placebo-controlled Trial on the Efficacy and Safety of Lopinavir / Ritonavir Plus Ribavirin in the Treatment of Severe Acute Respiratory SyndromeSevere Acute Respiratory SyndromeNCT00578825Hospital Authority, Hong Kong340
Completed
Phase 2
Ribavirin and Hedgehog Inhibitor With or Without Decitabine in AMLAcute Myeloid LeukemiaNCT02073838Sarit Assouline23
Completed
Phase 3
Study of Post-Exposure Ingavirin® Prophylaxis of Influenza and Acute Respiratory Viral InfectionsInfluenza, HumanAcute Respiratory InfectionFluViral InfectionCommon ColdNCT03189537Valenta Pharm JSC400